96 related articles for article (PubMed ID: 23174190)
1. Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3.
Piazza F; Manni S; Semenzato G
Leuk Res; 2013 Feb; 37(2):221-7. PubMed ID: 23174190
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.
Piazza F; Manni S; Ruzzene M; Pinna LA; Gurrieri C; Semenzato G
Leukemia; 2012 Jun; 26(6):1174-9. PubMed ID: 22289987
[TBL] [Abstract][Full Text] [Related]
4. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
[TBL] [Abstract][Full Text] [Related]
5. Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.
Manni S; Carrino M; Piazza F
J Hematol Oncol; 2017 Oct; 10(1):157. PubMed ID: 28969692
[TBL] [Abstract][Full Text] [Related]
6. Supervision of multiple signaling protein kinases by the CK2-Cdc37 couple, a possible novel cancer therapeutic target.
Miyata Y; Nishida E
Ann N Y Acad Sci; 2004 Dec; 1030():150-7. PubMed ID: 15659792
[TBL] [Abstract][Full Text] [Related]
7. Pyrrolidine dithiocarbamate-induced neuronal cell death is mediated by Akt, casein kinase 2, c-Jun N-terminal kinase, and IkappaB kinase in embryonic hippocampal progenitor cells.
Min YK; Park JH; Chong SA; Kim YS; Ahn YS; Seo JT; Bae YS; Chung KC
J Neurosci Res; 2003 Mar; 71(5):689-700. PubMed ID: 12584727
[TBL] [Abstract][Full Text] [Related]
8. Signalling and survival pathways in multiple myeloma.
Bommert K; Bargou RC; Stühmer T
Eur J Cancer; 2006 Jul; 42(11):1574-80. PubMed ID: 16797970
[TBL] [Abstract][Full Text] [Related]
9. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
10. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Younes H; Leleu X; Hatjiharissi E; Moreau AS; Hideshima T; Richardson P; Anderson KC; Ghobrial IM
Clin Cancer Res; 2007 Jul; 13(13):3771-5. PubMed ID: 17606706
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 90 (Hsp90) regulates the stability of transforming growth factor beta-activated kinase 1 (TAK1) in interleukin-1beta-induced cell signaling.
Shi L; Zhang Z; Fang S; Xu J; Liu J; Shen J; Fang F; Luo L; Yin Z
Mol Immunol; 2009 Feb; 46(4):541-50. PubMed ID: 18950863
[TBL] [Abstract][Full Text] [Related]
12. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
13. Casein kinase 2 inhibition modulates the DNA damage response but fails to radiosensitize malignant glioma cells.
Kroonen J; Artesi M; Capraro V; Nguyen-Khac MT; Willems M; Chakravarti A; Bours V; Robe PA
Int J Oncol; 2012 Aug; 41(2):776-82. PubMed ID: 22614258
[TBL] [Abstract][Full Text] [Related]
14. IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma.
Kolosenko I; Grander D; Tamm KP
Curr Med Chem; 2014; 21(26):3042-7. PubMed ID: 24735367
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma cell survival relies on high activity of protein kinase CK2.
Piazza FA; Ruzzene M; Gurrieri C; Montini B; Bonanni L; Chioetto G; Di Maira G; Barbon F; Cabrelle A; Zambello R; Adami F; Trentin L; Pinna LA; Semenzato G
Blood; 2006 Sep; 108(5):1698-707. PubMed ID: 16684960
[TBL] [Abstract][Full Text] [Related]
16. Emerging pathways as individualized therapeutic target of multiple myeloma.
Misso G; Zappavigna S; Castellano M; De Rosa G; Di Martino MT; Tagliaferri P; Tassone P; Caraglia M
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S95-109. PubMed ID: 23738692
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic approaches to myeloma bone disease: an evolving story.
Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
[TBL] [Abstract][Full Text] [Related]
18. [Molecular pathogenesis of myeloma for the therapeutic targets].
Hanamura I
Nihon Rinsho; 2007 Dec; 65(12):2202-8. PubMed ID: 18069261
[TBL] [Abstract][Full Text] [Related]
19. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
20. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
